It Might Be Too Late to Close the Barn Door on CRISPR Medical Treatments and That Seems Like Good News
Updates on CRISPR genetic engineering approaches.
Photo Credit: Singularity Hub
As we promised at “Don’t Count Us Out Yet,” we want to keep you updated on the big changes happening in the medical field due to CRISPR genetic engineering breakthroughs.
We still remain skeptical on some of the medical approaches using these breakthroughs, and we hope to continue to see the medical establishment proceed with caution. However, based on the news we get on an ongoing basis, the world is definitely out of the experimental stage and in the phase of conducting large scale trials to look at the benefits and risks of this new technology.
Consider the following news we have seen published in the last month.
A CRISPR approach has identified the cells that regulate resistance to breast cancer drug treatment. The approach may perhaps find a solution as to why one third of breast cancer patients over time develop resistance to the effectiveness of the drugs.
Due to the lack of solutions to some blood and bone leukemia diseases, Intellia’s CRISPR-engineered cell therapy fast tracks orphan drug approval from the FDA.
A group from the University of Texas at Austin has discovered a way to lessen, by 4,000 times, the negative consequence of CRISPR gene editing making a wrong edit that might cause the growth of other cancer cells.
Finally, here is an update of 26 non-COVID-19 related clinical trials from February, which has two negative trial results, about 10 that are still in startup and the rest showing positive results.
These results aren’t just in cancer, but reduction of heart disease, psoriasis, respiratory viruses that lead to pneumonia, Alzheimer’s and multiple sclerosis to name a few.
Our conclusion for readers is that these CRISPR trials have real results and are happening very fast. If you or anyone is diagnosed with a serious disease, make sure you are aware of CRISPR possible trials to at least consider if they can help.
Best,
Craig